Nitrosamine impurities have become one of the most closely scrutinized classes of pharmaceutical contaminants due to their potential carcinogenic risk and increasing regulatory attention. Following several high-profile product recalls, pharmaceutical manufacturers have implemented extensive risk assessment and testing programs to identify and control potential sources of nitrosamine formation. Most discussions surrounding nitrosamines focus on manufacturing […]